Infect Chemother.
2021 Mar;53(1):166-219. 10.3947/ic.2021.0303.
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
- Kim SB
1 - Ryoo S2
- Huh K3
- Joo EJ4
- Kim YJ5
- Choi WS1
- Kim YJ6
- Yoon YK1
- Heo JY7
- Seo YB8
- Jeong SJ9
- Park Da2
- Yu SY2
- Lee HJ2
- Kim J2
- Jin Y2
- Park J2
- Peck KR3
- Choi M2
- Yeom JS9
- D
- Affiliations
-
- 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- 2Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea
- 3Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 4Division of Infectious Diseases, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung hospital, Seoul, Korea
- 5Division of Infectious Diseases, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 6Division of Infectious Diseases and Immunodeficiency. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 7Department of Infectious Diseases, Ajou University school of Medicine, Suwon, Korea
- 8Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
- 9Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2514847
- DOI: http://doi.org/10.3947/ic.2021.0303
Abstract
- Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Response Guidelines for Coronavirus Disease 2019 in Newborn Infants: A 2021 Update
- Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARSCoV-2 Monoclonal Antibody Treatment of Patients with COVID-19
- Evidence-Developing Disease Control of Coronavirus Disease 2019
- Changes in the Incidence of Intussusception and Infectious Diseases After the COVID-19 Pandemic in Korea
- How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea
